Keros Therapeutics, Inc.
KROS
$14.16
$0.120.86%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 211.25M | 3.04M | 388.00K | 37.00K | 83.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 211.25M | 3.04M | 388.00K | 37.00K | 83.00K |
| Cost of Revenue | 48.71M | -128.00M | 49.23M | 40.52M | 38.26M |
| Gross Profit | 162.54M | 131.04M | -48.84M | -40.48M | -38.18M |
| SG&A Expenses | 10.50M | 10.67M | 9.82M | 9.96M | 10.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.21M | 56.30M | 59.05M | 50.48M | 48.57M |
| Operating Income | 152.04M | -53.25M | -58.66M | -50.44M | -48.48M |
| Income Before Tax | 158.49M | -45.73M | -52.96M | -45.26M | -43.11M |
| Income Tax Expenses | 10.04M | 300.00K | -- | -- | -- |
| Earnings from Continuing Operations | 148.45M | -46.03M | -52.96M | -45.26M | -43.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 148.45M | -46.03M | -52.96M | -45.26M | -43.11M |
| EBIT | 152.04M | -53.25M | -58.66M | -50.44M | -48.48M |
| EBITDA | 152.38M | -52.92M | -58.34M | -50.13M | -48.21M |
| EPS Basic | 3.66 | -1.14 | -1.41 | -1.25 | -1.21 |
| Normalized Basic EPS | 2.44 | -0.71 | -0.88 | -0.78 | -0.76 |
| EPS Diluted | 3.62 | -1.14 | -2.82 | -1.25 | -1.21 |
| Normalized Diluted EPS | 2.41 | -0.71 | -0.88 | -0.78 | -0.76 |
| Average Basic Shares Outstanding | 40.56M | 40.34M | 37.59M | 36.10M | 35.69M |
| Average Diluted Shares Outstanding | 41.02M | 40.34M | 37.59M | 36.10M | 35.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |